Pelemed

Pelemed is a South Korean biotechnology company specializing in the discovery and development of next-generation small molecule kinase inhibitors. Utilizing its proprietary Pel-SML (Structure-based Molecular Library) platform, the company focuses on overcoming drug resistance in oncology and addressing unmet needs in fibrotic diseases. Its lead candidate, PLM-101, is a dual FLT3/AXL inhibitor currently in Phase 1 clinical development for the treatment of acute myeloid leukemia. Pelemed's strategy involves structure-based drug design to achieve high selectivity and potency against challenging targets. The company is also advancing programs for solid tumors and non-alcoholic steatohepatitis (NASH).